Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 10, 2024

Aardvark Therapeutics secures $85m in Series C funding round

Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.

Continue
The company plans to allocate the Series C funds primarily towards concluding the clinical trials. Credit: National Cancer Institute on Unsplash.
May 9, 2024

IMA Life to build new pharma freeze-drying equipment production site

Artist’s rendering of IMA Life North America’s new $30m production facility in Tonawanda, New York. Credit: Governor Kathy Hochul/Empire State Development/IMA Life North America.
May 8, 2024

ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal

The companies will partner to develop and commercialise TriCAR-T cell immunotherapy targeting leukaemia and lymphoma. Credit: National Cancer Institute on Unsplash.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. OverT Bio secures $16m in seed funding for cell therapy development
  2. FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours
  3. Latus Bio secures $54m for CNS gene therapy development
  4. Celltrion secures new public tenders for two biosimilars in Peru
  5. Scenic Biotech, Bristol Myers Squibb to develop new drug targets

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation